ESMO shared a post on X:
“ESMO Breast 2026: Data from two trials of sequential TOPO1 ADC therapy in metastatic Breast Cancer suggest the emergence of payload cross-resistance, despite differing Monoclonal Antibody targets, as discussed by Thomas Grinda in the ESMO Daily Reporter.”
To which Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, added:
“Great perspective by Thomas Grinda on the SATEEN and HER3DXd post-ADC trials, both providing prospective data on TOPO1 ADCs after prior T-DXd. Switching ADC target does not seem to be the answer to overcome resistance, if the payload has a similar mechanism of action.”
Other articles featuring Paolo Tarantino and ESMO on OncoDaily.